<DOC>
	<DOCNO>NCT00362323</DOCNO>
	<brief_summary>To demonstrate patient T2DM dyslipidemia appropriately control statin receiving metformin , superiority fix combination fenofibrate metformin v metformin alone TG additionally , superiority TG establish , demonstrate superiority HDL-C</brief_summary>
	<brief_title>Fenofibrate Metformin Fixed Combination v Metformin - FAME METFO</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Metabolic Diseases</mesh_term>
	<mesh_term>Glucose Metabolism Disorders</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Fenofibrate</mesh_term>
	<criteria>Inclusion Criteria Patient Type 2 Diabetes treat stable dose metformin dyslipidemia appropriately control statin treatment . Exclusion Criteria Type 1 diabetes .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Treatment Dyslipidemia Type 2 Diabetes Mellitus</keyword>
</DOC>